🇺🇸 FDA
Pipeline program

SL TNX-102 2.4 mg at pH 3.5

TNX-CY-F102

Phase 1 small_molecule completed

Quick answer

SL TNX-102 2.4 mg at pH 3.5 for Healthy Adults is a Phase 1 program (small_molecule) at Tonix Pharmaceuticals Holding with 1 ClinicalTrials.gov record(s).

Program details

Company
Tonix Pharmaceuticals Holding
Indication
Healthy Adults
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials